AdvanCell Achieves Major Funding Milestone
AdvanCell, a pioneering clinical-stage radiopharmaceutical company dedicated to revolutionary cancer treatments, has successfully concluded an oversubscribed Series C financing totaling US$112 million. This significant funding round was co-led by notable investors SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis, with additional contributions from existing supporter Morningside and new entities including Tenmile and Brandon Capital.
Accelerating Growth and Expansion
Since its inception in 2019, AdvanCell has transitioned from a vision centered on Targeted Alpha Therapy to becoming a key player in the oncology field, bolstered by a dedicated team of 60 professionals and a high-tech 40,000-square-foot manufacturing facility. The company boasts advanced pre-clinical infrastructure and has developed a promising drug aimed at treating prostate cancer that is currently undergoing clinical trials. Furthermore, AdvanCell possesses a growing pipeline of innovative therapeutic assets.
Manufacturing Capacity and Clinical Development
This recent infusion of capital is set to significantly enhance AdvanCell's capabilities by allowing for expanded manufacturing operations and accelerating the clinical development of its radionuclide therapies. The company is driven by a mission to provide transformative treatments that positively impact the lives of cancer patients on a global scale.
Clinical Trials and Innovations
At present, AdvanCell is in the process of enrolling patients for the highest dose cohort in its multi-center TheraPb Phase I/II clinical trial. This trial focuses on ADVC001, a cutting-edge Targeted Alpha Therapy for metastatic prostate cancer, aiming to showcase the safety and effectiveness of Pb-212-based radionuclide treatment.
Strengthening Leadership and Expertise
As part of the funding arrangement, three new members have joined AdvanCell's Board of Directors: Jamil M. Beg from SV Health Investors, Christopher Gagliardi from Sanofi Ventures, and Bali Muralidhar from Abingworth. These experienced professionals will contribute valuable industry insights to steer AdvanCell's development alongside existing directors such as Bill Ferris AC, Anthony Aiudi, Kevin Cameron, and Andrew Adamovich.
Investors' Perspective
Jamil M. Beg, a Partner at SV Health Investors, expressed enthusiasm for being part of AdvanCell's growth journey. He emphasized the confidence SV Health Investors has regarding AdvanCell's Pb-212-PSMA program and its manufacturing platform. He noted that AdvanCell's robust infrastructure, collaborations with major pharmaceutical companies, and a dedicated team place it at the forefront of changing outcomes for patients, underscoring their commitment to improving cancer treatments on a global scale.
Commitment to Patients and Innovation
AdvanCell's foundation is rooted in the belief that Targeted Alpha Therapies can significantly alter cancer treatment approaches. The company’s focus on ensuring a scalable supply of isotopes drives its ambition to develop groundbreaking drugs. Their work in radionuclide therapies has already shown promising results in treating patients with prostate cancer and gastroenteropancreatic neuroendocrine tumors. The potential of Pb-212 Targeted Alpha Therapy to advance treatment options, by utilizing the unique radiobiological properties of Pb-212, offers hope for patient care.
Leadership’s Vision
In a statement reflecting on the successful Series C funding, AdvanCell’s CEO Andrew Adamovich articulated their gratitude for existing and new investor support. He noted that this funding positions AdvanCell well to enhance its operations and bring its pioneering therapies closer to commercialization, which aligns with their vision of transforming cancer care.
A Step Towards Leadership in Cancer Therapy
The completion of this Series C funding is indeed a pivotal moment in AdvanCell's development, setting the stage for the company to emerge as a leader in radionuclide-based cancer therapeutics. As they work towards enhancing patient care with innovative therapies, AdvanCell is on a mission to leave a lasting impact in the oncology field.
Frequently Asked Questions
What is AdvanCell known for?
AdvanCell is recognized for developing pioneering cancer therapies utilizing targeted alpha-emitting radionuclides aimed at significantly improving patient outcomes.
How much funding did AdvanCell secure in Series C financing?
The company secured US$112 million in its oversubscribed Series C financing round to enhance its operations and accelerate drug development.
What is the focus of AdvanCell's current clinical trial?
The current clinical trial focuses on ADVC001, a Targeted Alpha Therapy designed for the treatment of metastatic prostate cancer.
Who are the new members of AdvanCell's Board of Directors?
New members include Jamil M. Beg, Christopher Gagliardi, and Bali Muralidhar, all bringing valuable expertise to the board.
What is the potential impact of Pb-212 therapy?
Pb-212 therapy has the potential to change cancer treatment by harnessing its unique radiobiological properties to create effective treatment options for patients.
